Stocks Health care LIMN
NASDAQ · Health careLiminatus Pharma, Inc. (LIMN)
It posted a net loss of $12.5M. In fiscal 2025 capital spending exceeded operating cash flow by $10M. At June 30, 2026 it held $3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Liminatus Pharma, Inc. does
Liminatus Pharma, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker LIMN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$10.2M | -$0.43 | -$10M |
| 2025 | n/a | -$3.5M | -$0.20 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Liminatus Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 18, 2026
- August 14, 2026
- August 4, 2026
- July 30, 2026Other event 8-K
- July 24, 2026
- July 22, 2026Passive stake (5% or more) SCHEDULE 13G
- July 14, 2026Activist stake changed SCHEDULE 13D/A
- July 13, 2026Proxy statement DEF 14A
- July 6, 2026Passive stake changed SCHEDULE 13G/A
- July 6, 2026
Insider trades
What the people running Liminatus Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 2, 2026 | Valetudo Therapeutics LLCOfficer, Director, 10% owner | Other change | 3,448,926 | - |
| June 24, 2026 | Valetudo Therapeutics LLCOfficer, Director, 10% owner | Other change | 4,373,603 | - |
Who owns LIMN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Valetudo Therapeutics LLC13D, may seek influence with 1 related filers | 14.3% | July 14, 2026 |
| Ewon Comfortech Co., Ltd.13G, passive | 10.9% | July 6, 2026 |
| Samda Biolab Co., Ltd.13G, passive | 5.1% | July 22, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 5,244,351 shares in total, about $22M at the last price.
| Holder | Shares |
|---|---|
| Valetudo Therapeutics LLCOfficer, Director, 10% owner | 5,244,351 |
Questions about LIMN
What does Liminatus Pharma, Inc. do?
Liminatus Pharma, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker LIMN.
Is Liminatus Pharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $12.5M.
When did Liminatus Pharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from August 18, 2026.
Similar companies
Compare LIMN with
Follow LIMN
Get an email when Liminatus Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow LIMN: get an email when it filesWhere the numbers come from
Financial figures are the values Liminatus Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.